Position Statements

• Arrangements in place for monitoring threats to the UK blood supply from new and emerging infections (May 2024)
   
• Blood donor selection to minimise risk of transfusion transmissible infectious agents entering the blood supply (June 2020)
   
• Calcium Abnormalities and Apheresis Donation (June 2017)
   
• Chikungunya Virus (May 2024)
   
• COVID-19 Vaccines and Blood Transfusion (including Pre-deposit Autologous and Directed Donations) (September 2024)
   
• Dengue Virus (September 2024)
   
• Ebola Virus (September 2024)
   
• The estimated residual risk that a donation made in the infectious window period is not detected on testing: risks specific for HBV, HCV and HIV in the UK, 2021-2023 (September 2024)
   
• Granulocyte Therapy (March 2021)
   
• Guidance for the addition and removal of an infectious disease risk entry in the Geographical Disease Risk Index (GDRI) (May 2024)
   
• Horizon Scanning: Preparedness for emerging infectious agents (January 2024)
   
• Human Herpesvirus-8 (October 2023)
   
• Mpox Virus (MPXV) (September 2024)
   
• Perfluoroalkyl and polyfluoroalkyl substances (PFAS) (May 2023)
   
• SARS-CoV-2/COVID-19 and the Safety of Substances of Human Origin (SoHO) (May 2024)
   
• Transgender and Non-Binary Donors (April 2024)
   
• Variant Creutzfeldt-Jakob Disease (vCJD) (September 2024)
   
• West Nile Virus (September 2024)
   
• X-ray irradiation of blood components (June 2020)
   
• Zika Virus (September 2023)